AstraZeneca's (AZN) Tagrisso sNDA Gets FDA's Priority Tag

AstraZeneca (AZN) announced that the FDA has accepted its supplemental new drug application (sNDA), seeking expanded use of its blockbuster lung cancer drug, Tagrisso (osimertinib) in EGFR-mutated lung cancer.The sNDA is seeking approval for Tagrisso for the treatment of adult patients with unresectable, stage III EGFR-mutated non-small cell lung cancer (NSCLC) following treatment with chemoradiotherapy (CRT).With the FDA granting a priority review to the sNDA, a decision from the regulatory body is expecte ...